Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VYVANSE

« Back to Dashboard

Summary for Tradename: VYVANSE

Patents:18
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$1,743,115,000

Pharmacology for Tradename: VYVANSE

Clinical Trials for: VYVANSE

Effect of Vyvanse on Driving in Young Adults With ADHD
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder(ADHD)

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder; Sleep

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
Status: Completed Condition: Healthy Volunteers

Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
Status: Terminated Condition: Bipolar Depression

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence
Status: Completed Condition: Cocaine Dependence

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Status: Completed Condition: Attention Deficit Hyperactivity Disorder (ADHD)

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
Status: Recruiting Condition: Attention Deficit Hyperactivity Disorder

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
Status: Terminated Condition: Attention Deficit Hyperactivity Disorder; Glucose Intolerance; Obesity

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
Status: Completed Condition: Attention Deficit/Hyperactivity Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Feb 23, 2007RXYes7,662,787<disabled>Y<disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Feb 23, 2007RXNo7,655,630<disabled>Y<disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Dec 10, 2007RXNo7,662,788<disabled><disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Feb 23, 2007RXYes7,671,031<disabled><disabled>
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977Feb 23, 2007RXYes7,223,735<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VYVANSE

Drugname Dosage Strength RLD Submissiondate
lisdexamfetamine dimesylateCapsules20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mgVyvanse2/23/2011
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc